Published: 27 August 2022
Author(s): Shingo Kato, Nobuyuki Horita, Daisuke Utsunomiya
Section: Letter to the Editor

Coronary computed tomography angiography (CTA) screening for coronary artery disease (CAD) is an indispensable diagnostic tool in clinical practice because of its excellent negative predictive value and ability to exclude critical CAD. Recently, there has been increasing interest amongst clinicians and researchers in understanding the prognostic impact of coronary CTA on improving clinical outcomes and, to this end, three randomized controlled trials (RCTs): PROMISE [1], SCOT-HEART [2], and DISCHARGE [3], have been conducted to date.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.